Conatus Announces Pricing of Public Offering of Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Conatus Announces Pricing of Public Offering of Common Stock

SAN DIEGO, April 2, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT ), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it has priced an underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $5.75 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be approximately $20.1 million.

Conatus intends to use the net proceeds from the offering to fund clinical development of emricasan, including preparation for registration trials, and for working capital and other general corporate purposes. Conatus has granted the underwriters a 30-day option to purchase up to 525,000 additional shares of its common stock. The offering is expected to close on or about April 8, 2015, subject to satisfaction of customary closing conditions.

Stifel and Roth Capital Partners are acting as book-running managers for the offering.

The securities described above are being offered by Conatus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained, when available, from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com , or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660 or by telephone at (800) 678-9147. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov .

About Conatus Pharmaceuticals

Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Conatus' expectations on the completion, timing and size of the public offering and the anticipated use of proceeds therefrom. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Conatus' business, including those described in the company's periodic filings with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

MEDIA: David Schull Russo Partners, LLC (858) 717-2310 INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 81

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 141

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 47

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 144

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 37

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

ADT Inc. Pricing for Secondary Offering and Share Repurchase

Updated Category News Views 210

ADT Inc. Moves Forward with Secondary Public Offering ADT Inc. (NYSE: ADT) has made waves in the financial world by announcing the pricing of a secondary public offering. This significant event involves 56 million shares of common stock that are being sold by certain entities associated with Apollo Global Management, Inc. The process is designed to provide liquidity and...

Continue Reading
Exciting Updates from illumin Holdings Regarding Q2 2025 Results

Updated Category News Views 176

Upcoming Financial Results Announcement Toronto and New York - illumin Holdings Inc. (TSX: ILLM, OTCQB: ILLMF), renowned in the digital advertising technology sector, is gearing up to present its second quarter 2025 financial outcomes. These results are set to be unveiled before market operations commence on an announced date. Join Us for the Live Webcast All interested...

Continue Reading
Exploring Growth in the Mining Remanufacturing Sector

Updated Category News Views 168

Understanding the Mining Remanufacturing Components Market This comprehensive analysis provides insights into the growth of the mining remanufacturing components market. It highlights the increasing demand for sustainable practices, innovations, and market dynamics. Market Size and Growth Rate The mining remanufacturing components market was valued at around US$ 4.20...

Continue Reading
Novo Nordisk's Wegovy Trial Success: Weight Loss Breakthrough

Updated Category News Views 787

Groundbreaking Results from Novo Nordisk's Wegovy® Trial The latest findings from Novo Nordisk indicate a significant breakthrough in weight management through the higher dose of Wegovy, which has delivered an impressive average weight loss of 21% for individuals suffering from obesity. The trial results, presented at a prominent diabetes conference, revealed that...

Continue Reading
Builders FirstSource Announces Leadership Transition Plans

Updated Category News Views 230

Leadership Changes at Builders FirstSource Builders FirstSource, Inc. (NYSE: BLDR) is undergoing a major leadership shift as part of a planned transition. The company has announced that Peter Jackson, who currently serves as the Chief Financial Officer, will step into the role of President and Chief Executive Officer. This change marks an important milestone in the...

Continue Reading